GRC and Total Data Centre Solutions Partner to Expand Data Centre Liquid Immersion Cooling in Europe
GRC (Green Revolution Cooling), the single-phase immersion-cooling authority® for data centres, today announces a new partnership contract with Total Data Centre Solutions (TDCS), a leading provider of mission critical and innovative infrastructure solutions for Data Centres throughout Europe and the Nordic region focused on carbon reduction and energy efficiency.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201019005928/en/
GRC ICEraQ immersion-cooling system with rack-mounted service rails for easy maintenance and hot swaps. (Photo: Business Wire)
Through the partnership, TDCS will act as the agent for GRC in Europe, selling GRC’s ICEraQ® Micro-Modular, Rack-Based Immersion-Cooling Systems and ICEtank® Modular, Containerised data centres to clients primarily in the UK, the Nordic region, Germany and Luxembourg. Additionally, this new partnership now enables GRC to engage and support European data centre customers with a local European presence.
“GRC is delighted to partner with TDCS,” said Jim Weynand, Chief Revenue Officer, GRC. “The proliferation of AI, 5G, Edge computing, reduced carbon emissions, and more throughout Europe present new challenges for both legacy and new data centre builds. Our partnership with TDCS will ensure clients throughout Europe can seamlessly integrate immersion cooling into their existing infrastructures.”
After thoroughly assessing various immersion cooling solutions on the market, TDCS recognized that GRC’s immersion-cooling technology is a differentiator that brings value to their existing and potential clients. European clients can now acquire GRC’s immersion-cooling systems through TDCS in order to reduce energy use or power consumption, solve power and space density challenges, cut energy cooling costs significantly and place HPC compute close to where it’s needed and secure other benefits of GRC’s game-changing immersion-cooling solutions. Being the longest established immersion cooling company, with 11+ years’ experience and many blue-chip clients including The US Government, the US Air Force, and approved by most global server manufacturers – take out the fan and reap all the awards.
“It’s exciting to build this new partnership with GRC,” said Jonathan Evans, Founder of TDCS. “Joining GRC as an agent partner is an opportunity for us to offer clients best-of-breed single-phase liquid immersion cooling technology. We are passionate about reducing the carbon footprint and the OpEx of each, of our clients. The partnership of GRC and TDCS helps solve carbon and cost issues facing all data center owners and operators, which perfectly complements our sustainability portfolio of offerings from technologies to data centres."
About GRC
GRC is the immersion cooling authority®. The company's patented immersion-cooling technology radically simplifies deployment of data centre cooling infrastructure. By eliminating the need for chillers, CRACs, air handlers, humidity controls and other conventional cooling components, enterprises reduce their data centre design, build, energy, and maintenance costs. GRC’s solutions are deployed in seventeen countries and are ideal for next-gen applications platforms, including artificial intelligence, blockchain, HPC, 5G, and other Edge Computing and core applications. Their systems are environmentally resilient, sustainable, and space saving, making it possible to deploy the solution in virtually any location with minimal lead time. Visit http://grcooling.com for more information.
About Total Datacentre Solutions
TDCS is an End to End Data Centre Consultancy, founded in 2002. Specialising in reducing a client’s IT carbon footprint and CapEx/OpEx with new technologies. TDCS comprises a team of data centre business professionals, many with 30+ years of industry experience. Our aim is to provide clients with innovative technologies to help reduce their carbon footprints and optimize their CapEx/OpEx. Visit https://www.totaldatacentresolutions.co.uk for more information
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201019005928/en/
Contact information
Milldam Public Relations
Adam Waitkunas
978-828-8304 (mobile)
adam.waitkunas@milldampr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Announces Positive Topline Results for Sonrotoclax in Relapsed or Refractory Mantle Cell Lymphoma (MCL)29.8.2025 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from a Phase 1/2 study (BGB-11417-201) of sonrotoclax, a next-generation and potentially best-in-class investigational BCL2 inhibitor, in adult patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL), following treatment with a Bruton’s tyrosine kinase inhibitor (BTKi) and anti-CD20 therapy. BeOne plans to present the full data at an upcoming medical meeting. “For people with relapsed or refractory mantle cell lymphoma, the disease is aggressive, the treatment landscape fragmented, and the outcomes unacceptably poor. These topline results for sonrotoclax underscore its potential to deliver meaningful and durable responses and offer the first BCL2 inhibitor for patients with R/R MCL, if approved,” said Lai Wang, PhD, Global Head of R&D, BeOne Medicines. “These data add to the remarkable progress we’ve seen over the past five years in treating B-cel
Oulu2026 – European Capital of Culture: Oulu to Unveil Full European Capital of Culture 2026 Programme – Live Stream on 4 September 202529.8.2025 11:46:00 EEST | Press release
Hundreds of partners are creating a year in which Northern Finland becomes a new hub of culture. The programme will offer something for everyone: large-scale exhibitions, festivals across all genres, world premieres, performing arts, village celebrations, permanent artworks, sports, and community events across a vast region of 40 municipalities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250829591577/en/ Oulu, with its 39 partner municipalities in Northern Finland, will step into the spotlight as European Capital of Culture 2026. The full programme will be officially launched on Thursday 4 September 2025 in Oulu, streamed live across Europe. The Oulu2026 programme is built around the theme of Cultural Climate Change, meaning a lasting enrichment of cultural life – connecting people through world-class experiences, creativity, and new ways of thinking. “2026 will be a transformative year – for our city, for Northern Finla
Nippon Sanso Holdings Group Unifies Global Brand Logo Launching the "NIPPON SANSO" Brand Worldwide29.8.2025 09:00:00 EEST | Press release
Nippon Sanso Holdings Corporation (President CEO: Toshihiko Hamada) will unify the brand logo for its industrial gas business globally and implement the change in stages. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250828253560/en/ Until now, our group has operated industrial gas businesses worldwide using the same symbol mark, while adapting to each region. To further enhance recognition and understanding of our group as a unified entity among a broad range of stakeholders, and to maximize corporate value and achieve sustainable growth, we have decided to unify the brand for our industrial gas businesses as "NIPPON SANSO" and standardize the brand logo globally. Moving forward, we will continue striving to be a trusted company for all stakeholders as a globally recognized brand. *Please note that Thermos Group, which operates the consumer household goods business within our group, will not change its brand logo. *The log
TOM FORD Unveils Black Orchid Reserve Campaign Starring Tilda Swinton29.8.2025 07:35:00 EEST | Press release
The quest for exceptional rarity. Introducing Tilda Swinton for the new TOM FORD Black Orchid Reserve campaign. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250828507187/en/ “It is a profound honour for me to play a part in the history of TOM FORD’s legendary Black Orchid. Transformation, the blurring of boundaries and the celebration of magical properties have always drawn me close; Black Orchid Reserve is precisely such an enchantment.” — Tilda Swinton A celebrated actor and artist, Swinton is a singular presence known for her fearless artistry and transformative performances. An Academy Award, BAFTA and Golden Lion for Lifetime Achievement winner, Swinton defies conventions with elegance, intellect and a visionary approach to cinema. Her work transcends definition, shaping the culture through work in film, art and performance. TOM FORD creative director Haider Ackermann designed the campaign as a cinematic portrait of r
Novotech Supports Groundbreaking Approval of Anlotinib Combination Therapy for Advanced Soft Tissue Sarcoma28.8.2025 23:15:00 EEST | Press release
Novotech, a globally recognized full-service clinical research organization (CRO), is proud to have partnered with Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CTTQ Pharma) in achieving a significant regulatory milestone: the approval of Anlotinib Hydrochloride Capsules for a new indication as a first-line treatment for unresectable locally advanced or metastatic soft tissue sarcoma (STS) in combination with chemotherapy. This approval marks the ninth indication for Anlotinib in China and represents the world’s first official approval of an Anlotinib-chemotherapy combination for first-line treatment of advanced or metastatic STS. Previously recommended as a second-line monotherapy by the Chinese Society of Clinical Oncology (CSCO) guidelines, Anlotinib was the only Grade I targeted therapy for STS. This new indication represents a significant advancement for patients who have not previously received systemic treatment, expanding access to more effective and targeted first-line the
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom